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Streptococcus agalactiae or group B streptococcus (GBS) is a leading 
cause of invasive disease, particularly in newborns. GBS can also 
cause infections such as chorioamnionitis, endometritis, puerperal 
sepsis and urinary tract infection in pregnant women, which may 
be associated with poor fetal outcome.[1,2] Seventy-five percent of 
neonates will be colonised by mothers carrying the organism. One 
to two percent of these babies will develop GBS early-onset disease 
(GBS-EOD), which manifests within the first 7 days of life.[3] In GBS-
EOD, neonates typically present with sepsis and pneumonia and 
less frequently with meningitis. The case fatality rate of GBS-EOD 
ranges from 11% to ~50%.[1,2] The incidence of GBS-EOD varies 
considerably depending on geographical location, but is thought to 
be ~2/1 000 live births in South Africa (SA).[4]
The Centers for Disease Control and Prevention (CDC)[5] 
recommends screening pregnant women at 35 - 37 weeks’ gestation 
by obtaining a single vaginorectal swab or separate vaginal and 
rectal swabs for culture. The swabs should be inoculated into a 
selective broth medium such as Lim Broth for 18 - 24 hours followed 
by subculture onto a blood agar plate which is incubated for 18 - 
24 hours and should be observed for beta-haemolytic GBS colonies. [5] 
Further tests need to be performed to confirm GBS, such as the 
Christie-Atkins-Munch-Peterson (CAMP) test, hippurate hydrolysis 
and/or latex agglutination. Women found to be colonised with GBS 
prenatally are given intrapartum antibiotic prophylaxis (IAP). This 
measure has been proven to decrease the incidence of GBS-EOD 
in neonates.[5] According to the CDC, penicillin remains the agent 
of choice for IAP.[5] Erythromycin and clindamycin are alternatives 
for penicillin-allergic women and should be administered only after 
susceptibility results are available.[5] There are no SA guidelines for IAP.
Various selective media are used to isolate GBS. These include 
CHROMagar StrepB (CHROMagar, France) ChromID Strepto B 
agar (bioMérieux, France) and the Granada medium (bioMérieux, 
France). Rosa-Fraile et al.[6] compared the Granada medium with 
Todd-Hewitt broth followed by subculture on blood agar medium to 
detect GBS colonisation in pregnant women. The Granada medium 
was found to be more sensitive than the selective broth for the 
detection of GBS in vaginorectal samples (96% v. 82%). In addition, 
the use of Granada medium improved the time to reporting of a 
GBS-positive result by at least 24 hours and reduced the direct cost of 
screening.[6] A 2014 Japanese study[7] showed that ChromID Strepto 
B agar had a higher detection rate than blood agar with enrichment. 
Furthermore, the medium produced fewer false negatives after an 
extended incubation period.[7] The use of culture as a gold standard 
to detect GBS colonisation necessitates a longer incubation period of 
up to 48 hours depending on the culture medium used. This results 
in a prolonged turnaround time of results, which may lead to delayed 
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Background. Group B streptococcus (GBS) is a leading cause of invasive disease, particularly in newborns. Seventy-five percent of neonates 
will be colonised by mothers carrying the organism. Confirmation of maternal colonisation with GBS is essential for prompt treatment and 
prevention of neonatal sepsis. The current gold standard of culture for isolation of GBS has a disadvantage of long turnaround time (24 - 
72 hours). Rapid assays are required to determine maternal carriage of GBS.
Objectives. To determine the usefulness of the Xpert GBS technology v. culture methods to detect GBS carriage in pregnant women.
Methods. This was a prospective observational study of 284 pregnant women between 26 and 37 weeks’ gestation. Two vaginorectal 
swabs were collected from each participant. One swab was processed using the gold-standard culture method, while the second swab was 
processed using the Xpert GBS assay. The performance of the Xpert GBS assay was then compared with that of the culture method.
Results. Two swabs were processed from each of 284 pregnant women between 26 and 37 weeks’ gestation. Culture detected 70 GBS isolates 
from a total of 279 specimens (25.1%), whereas the Xpert GBS detected 66 positive specimens (23.7%). The Xpert GBS assay had a sensitivity 
of 87% and specificity of 98%, with a positive predictive value of 92% and a negative predictive value of 96%.
Conclusions. The Xpert GBS assay is a rapid and sensitive tool for prenatal detection of GBS. The assay should ideally be available in every 
labour ward, where women can be screened for GBS on arrival.
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treatment of patients. In this case, patients at clinics may be sent 
home to come back for results and are very often lost to follow-up.
To overcome these challenges, more rapid and sensitive techniques 
have been developed, including molecular assays such as the Xpert 
GBS (Cepheid, USA). This is a real-time polymerase chain reaction 
(PCR) assay that amplifies the cfb gene to detect GBS directly from 
clinical samples with a turnaround time of 37 - 55 minutes.[8] Several 
studies evaluating the Xpert GBS found the assay to have sensitivities 
ranging from 85% to 98% and specificities of between 96% and 99% 
for the detection of GBS colonisation in pregnant women.[8-10] In 
a landmark study by El-Helali et al.[8] in France, it was found that 
identification of GBS-positive women in an intrapartum setting 
can be accurately achieved by the use of the Xpert GBS assay. In 
comparison with culture as a reference standard, they showed a very 
high sensitivity of 98.5% and specificity of 99.6% for the Xpert GBS 
assay.[8]
Objectives
To compare the Xpert GBS with culture using Granada medium for 
the detection of GBS colonisation in pregnant women. 
Methods
Study design and setting
This was a prospective, observational study conducted at the 
antenatal clinic at Kalafong Hospital, a tertiary hospital in Pretoria, 
SA, between November 2013 and May 2014. The study was not 
registered as a clinical trial.
Participants
Two hundred and eighty-four pregnant women aged >18 years and 
between 26 and 37 weeks’ gestation were enrolled in a convenience 
series for the study. Participants were only enrolled in the study after 
written informed consent had been obtained. Baseline demographic 
characteristics of patients were obtained from a questionnaire that 
was completed together with the informed consent form. Participants 
with missing data were excluded from the study.
Eligibility criteria included all pregnant women aged >18 years 
who were >26 weeks pregnant. We excluded women who had 
received antibiotics during the 2 weeks preceding enrolment, those 
who were part of a GBS vaccine trial and those who refused consent.
Kalafong Hospital has no screening policy for GBS in pregnancy, 
but a risk-based approach is used. With this approach, any woman 
presenting in labour with a history of prolonged rupture of 
membranes (>18 hours), previous GBS colonisation or fever will be 
prescribed antibiotics intrapartum.
Specimen collection
Fig. 1 illustrates the laboratory workflow. Vaginorectal swabs were 
collected using the Copan Venturi Transystem collection device 
(Copan Diagnostics, USA), which consists of a pair of rayon swabs 
in Stuart’s transport me dium. All swabs were collected after excessive 
secretions/discharge had been removed. The first swab was inserted 
into the vagina (posterior fornix) and the second into the rectum 
(~2.5 cm beyond the anal sphincter). All specimens were collected by 
the same clinician and were transported to the laboratory in a cooler 
box with ice packs within 4 hours of collection.
GBS culture
The Cepheid Collection Device consists of a pair of swabs in one 
device. On arrival at the laboratory, one swab was placed in the Xpert 
GBS cartridge and run on the GeneXpert module according to the 
manufacturer’s instructions. The second swab was plated on the 
Granada agar to do a ‘head-on’ comparison with the Xpert GBS. The 
Granada medium plates were incubated anaerobically at 35 - 37oC 
for 24 - 48 hours. Characteristic orange colonies on the Granada 
medium were confirmed to be GBS by Streptex latex agglutination 
(Remmel, UK).
Xpert GBS assay
The second paired vaginorectal swab was placed directly into the 
Xpert GBS cartridge and processed according to the manufacturer’s 
instructions. If an ‘invalid’ or ‘error’ result was generated, the test 
was repeated using the swab that was used for culture. Results were 
available between 37 minutes (GBS-positive) and 55 minutes (GBS-
negative).
As this was a laboratory-based observational study, positive results 
on Xpert GBS or culture were not communicated to the clinicians.
Sample size and statistical analysis
A minimal sample of 246 specimens would estimate the expected 
prevalence of 20% GBS colonisation in pregnant women at Kalafong 
Hospital to an accuracy of within 5% and a confidence interval of 
95%. The agreement between culture and Xpert GBS was assessed 
using Cohen’s kappa statistic. McNemar’s test for symmetry was 
also determined. Prevalence was reported as a percentage with a 
95% confidence interval. Diagnostic statistics (sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV)) 
were also calculated. Indeterminate results from the Xpert GBS were 
repeated. A subsequent indeterminate result was excluded from the 
final analysis.
Ethical approval
Ethical approval for this study was obtained from the Faculty of 
Health Sciences Research Ethics Committee, University of Pretoria 
(ref. no. 393/2013).
Results
Demographic characteristics of participants
The mean (standard deviation (SD)) age of the study participants was 
31.9 (5.57) years, and they had a mean (SD) number of 1.63 (1.05) 
A pair of swabs collected from 
pregnant women aged >18 years 
and between 26 and 37 weeks' gestation
1 swab placed into 
Xpert GBS cartridge
Result available 
within 55 minutes
Compare result with 
culture result +
Calculate prevalence of GBS 
carriage among pregnant 
women and calculate accuracy 
of Xpert GBS v. culture
1 swab used to 
inoculate Granada medium – 
incubate at 35 - 37oC under anaerobic 
conditions for 24 - 48 hours
Conrm typical orange colonies 
as group B streptococcus with 
Streptex agglutination kit
Compare results with 
Xpert GBS result
Fig. 1. Diagram illustrating laboratory workflow. (+ = positive.)
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live children; 25.0% reported a previous stillbirth or miscarriage, 
while only 5.0% reported a previous history of preterm labour. The 
proportion of primigravidas was 13.0%.
Culture v. Xpert GBS
Two hundred and eighty-four specimens were processed on both 
the Granada culture medium and Xpert GBS. Forty-three specimens 
(15.1%) had to be repeated on the Xpert GBS owing to an ‘invalid’ 
result, an ‘error’ or a ‘no result’ message from the system. Five samples 
did not generate a result on Xpert GBS despite repeat testing and were 
excluded from the analysis. The subsequent 5 unsuccessful attempts 
included 3 ‘errors’, 1 ‘invalid’ result and 1 ‘no result’. A total of 279 
specimen results were analysed. Interestingly, of the 5 inconclusive 
samples from Xpert GBS, 3 were negative on culture and 2 were 
positive.
Prevalence of GBS in pregnancy
The Granada medium supported the growth of 70 samples (25.1%), 
whereas the Xpert GBS detected 66 (23.7%) (Table 1). Nine samples 
(3.2%) were positive by culture but were not detected by Xpert GBS. 
Xpert GBS detected 5 (1.8%) positives that were not isolated by 
culture. Group B streptococcus was detected by both methods in 61 
samples (21.9%).
There were 3 instances where orange colonies were observed on the 
Granada medium but the confirmatory Streptex latex agglutination 
was negative. Two of the 3 isolates were further identified using the 
Vitek 2 system and were found to be Leuconostoc mesenteroides ssp. 
cremoris and S. thoraltensis. Both of these isolates were negative on 
the Xpert GBS. The third isolate was not identified by the Vitek 2 
system and was determined to be a bacillus species by 16SrRNA 
sequencing. This isolate was positive on the Xpert GBS.
Performance of Xpert GBS compared with culture
Results from the Xpert GBS assay were available as soon as 37 minutes 
in the case of a positive result, while the maximum time the assay 
took to give a result was 55 minutes. The time for each individual 
test was not recorded. The earliest that a culture result was available 
was 18 hours after incubation. Culture plates were monitored at 18, 
24 and 48 hours for growth; however, the time to positivity for each 
specimen was not documented.
Using the culture results as a gold standard, the Xpert GBS assay 
had a sensitivity of 87% and a specificity of 98%, with a PPV of 
92% and an NPV of 96%. Cohen’s kappa statistic was calculated to 
be 0.8639, which suggested excellent agreement (95%). McNemar’s 
test for symmetry was not significant (p=0.285), which suggests that 
the rates of positivity between the two tests (25% v. 24%) are not 
statistically significant.
Discussion
This is the first study that has been undertaken in Africa comparing 
the Xpert GBS and culture in determining GBS colonisation 
rates in pregnant women. The colonisation rate with GBS in 
this study was found to be 25% by culture and 24% by Xpert 
GBS. These findings are comparable with global colonisation rates 
ranging from 10% to 40%. [9] Studies undertaken in SA have shown 
colonisation rates of <30% in Durban[10] and Pretoria (M Chukwu 
et al., ‘Group B streptococcus in pregnant women and their babies 
at Dr George Mukhari Hospital, Pretoria’: unpublished Pathpoint 
poster presentation, 2012, Cape Town, South Africa). In a more 
comprehensive study undertaken in Soweto, Johannesburg, GBS 
colonisation rates were found to be 32.7% at 26 - 30 weeks’ gestation, 
28.7% at 31 - 35 weeks and 28.4% at ≥37 weeks.[11]
The Granada medium detected more positive GBS than the Xpert 
GBS (70 v. 66). The colonies on the medium were easily identified 
based on the orange colour. In addition, these colonies could be 
picked off without any difficulty. Twenty-four hours of incubation 
under anaerobic conditions was adequate and prolonged incubation 
was not necessary.
Initial Xpert GBS results were not available for 43 specimens 
(15.1%). In these cases, the instrument generated messages that 
included ‘error’ (24 specimens), ‘invalid’ (12 specimens) and ‘no result’ 
(6 specimens). These initial rates where results were unavailable were 
much higher than the 10.8% reported by El Helali et al.[8] or the 8.2% 
claimed by the manufacturer. However, they were found to be simi lar 
to rates reported in a Korean study by Park et al.[12] The major causes 
of invalid and error results were PCR inhibition and high syringe 
pressure exceeding the cut-off point, respectively. The presence of 
significant amounts of mucus or faeces in a sample is known to 
inhibit PCR and block the microfluidic channel in the cartridge. This 
effect was minimised in two ways. Firstly, excess mucus/secretions 
were wiped away at the point of collection, as recommended by 
the manufacturers. Secondly, a sterile gauze swab was used to wipe 
away excess mucus/faeces immediately prior to loading the swab 
into the Xpert GBS cartridge. The high error rate in this study could 
be a potential disadvantage to routine use of this assay as it would 
significantly escalate costs when repeat testing is warranted.
The cost of the Xpert GBS cartridge at the time of conducting this 
study was ZAR300.00 (USD30.45) per cartridge, whereas the cost of 
culture using Granada agar was ZAR19.00 - 154.00 (USD1.92 - 15.63) 
per test, depending on whether the CAMP test or latex agglutination 
was used to confirm the identity of the isolated colonies, respectively. 
Culture is therefore far cheaper, and this difference in cost will be 
more pronounced if repeat testing has to be done (15% of samples for 
Xpert GBS in this study).
The cost of the CDC-recommended culture method for screening 
for GBS is about the same as using Granada agar. The cost would 
amount to between ZAR19.75 and ZAR165.00 (USD2.00 - 16.75) 
per test depending on whether the CAMP test or latex agglutination 
is used to identify the colonies, respectively. It further has the 
disadvantage of a longer turnaround time of 48 - 72 hours compared 
with the Granada medium (24 - 48 hours).
The sensitivity of Xpert GBS compared with culture in this study 
(87%) was found to be lower than that detected in three other studies 
(95.8 - 98.5%),[8,13,14] but was comparable to the Korean study,[12] 
which showed a sensitivity of 86%. The specificity was consistent with 
other studies.[8,12-14]
Nine cases were Xpert GBS-negative and culture-positive. This 
could be due to the low bacterial load, which would be considered 
Table 1. Detection of GBS by culture and Xpert GBS
Samples, N
Culture-
positive, n (%)
Xpert GBS-
positive, n (%)
Xpert GBS-positive, 
culture-positive, n (%)
Xpert GBS-positive, 
culture-negative, n (%)
Xpert GBS-negative, 
culture-positive, n (%)
No results generated 
by Xpert GBS, n (%)
279 70 (25.1) 66 (23.7) 61 (21.9) 5 (1.8) 9 (3.2) 5 (1.8)
GBS = group B streptococcus.
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to be below the limit of detection of the assay. The limit of detection 
reported by Park et al.[12] was 300 colony-forming units per swab. In 
the 5 cases that were Xpert GBS-positive and culture-negative, it is 
possible that the Xpert GBS detected the cfb gene in non-viable GBS, 
or that other organisms such as enterococci hindered the isolation of 
GBS. Another possible explanation is that the Granada medium does 
not support the growth of non-haemolytic GBS colonies. Between 1% 
and 2% of GBS colonies are non-haemolytic.[15]
Although the Xpert GBS has been evaluated in other countries 
such as France and Korea, it is not used routinely in clinical 
practice. [8,12] In SA it is not even currently routine to screen for GBS 
in pregnancy in the public sector, let alone suggesting a method for 
screening. In our opinion, the current role of Xpert GBS is therefore 
for private obstetricians to use the test, either in their rooms or in 
the labour ward when a woman presents in labour. If GBS screening 
becomes routine practice in SA, the Xpert GBS could be considered as 
it can be used on the same machines/modules that are currently used 
to run the Xpert MTB/Rif test for tuberculosis. However, the cost of 
the cartridge will determine this.
The major advantage of the Xpert GBS assay is the rapid turnaround 
time of 37 - 55 minutes. It is also relatively easy to perform and 
therefore possible to use as a potential point-of-care assay. However, 
in resource-limited settings like SA, culture may be the only option 
available for the detection of GBS. This study clearly showed that the 
Granada medium has the advantage of easy and early detection of 
GBS with no significant escalation in the cost of culture.
Study limitations
A limitation was that this was a single-centre study. As a result, 
there could be a potential source of bias in the selection of patients. 
Another potential source of bias may be that participants were only 
selected from the antenatal clinic and not from other sites at Kalafong 
Hospital such as the labour ward or the obstetrics and gynaecology 
wards. A further limitation was that the exact running time for each 
Xpert GBS test was not recorded. As a result, we could not determine 
factors such as the median duration and interquartile range for this 
test. In addition, participants with missing data could have been 
traced back to retrieve the data. A shortcoming of the study design 
was that it was purely a laboratory-based study comparing two assays.
Conclusions
Compared with the standard culture method, the Xpert GBS assay 
is a rapid and sensitive tool for prenatal detection of GBS. Ideally, it 
is a point-of-care test that should be used in the labour ward when 
a patient presents in labour. In view of the high primary error rate 
(17%) experienced in our study, the financial feasibility of potential 
uses will need to be evaluated further.
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